RxDoctor Payments Data

Kareem Bannis, MD

Geriatric Medicine · Mesa, AZNPI 1134569494

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations.

$602in general payments, 2019–2025

Across 27 payments — averaging $22.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$105
  • Viiv Healthcare Company$101
  • Exact Sciences$92
  • Pfizer$77
  • Gilead$49
  • GSK$32
  • plus $145 from 7 others

What the payments were for

  • Food & beverage$59098%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$602 in reported general payments places this provider in the 70th percentile of 75 geriatric medicine providers in Arizona.

See all geriatric medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$392
Medicare patients
14
Services billed
31

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin42$63,180
OzempicSemaglutide20$46,368
TrulicityDulaglutide30$39,333
EliquisApixaban27$28,877
MounjaroTirzepatide20$27,116
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,392
Novolog FlexpenInsulin Aspart13$8,343
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$7,894
Humalog Kwikpen U-100Insulin Lispro14$7,659
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$5,695
Levemir FlexpenInsulin Detemir19$3,815
Atorvastatin Calcium339$3,336
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$3,057
Ultra-Fine Short Pen NeedlePen Needle, Diabetic37$2,590
Albuterol Sulfate HfaAlbuterol Sulfate84$2,381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$77$28,87727 claims
GSKTrelegy Ellipta$32$9,39213 claims
AbbVieSynthroid$105$1,32113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 75 geriatric medicine providers in Arizona.

Other geriatric medicine in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →